Diagnos Inc's stock saw modest movement this week amidst news of convertible debenture amendments.
On Friday, Diagnos Inc (ADK.V) closed at C$0.23 per share, reflecting a daily increase of 2.22%. Over the past week, the stock remained unchanged, while it has decreased by 36.11% year-to-date. The company recently made headlines with an announcement regarding amendments to its convertible debentures, which could influence investor sentiment.
Advertisement
Diagnos Inc
ADK.V
ADK.V
Diagnos Inc
WealthAwesomeAdvertisement
Market cap
$45.76M
52W high
$0.42
52W low
$0.18
1W change
+24.19%
Beta
-0.15
Analyst Price Targets
Based on analyst covering ADK
Wall Street analysts forecast ADK stock price to rise 289.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$1.50
+289.6% Upside
Current Price
C$0.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ADK's historical volatility
30-Day Vol
87.0%
Annualized
90-Day Vol
69.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.41 | C$0.30 – C$0.55 |
| 60 trading days | C$0.43 | C$0.28 – C$0.66 |
| 90 trading days | C$0.46 | C$0.27 – C$0.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Diagnos Inc's stock has seen a steady decline this year, recent news about its convertible debentures might signal investors to keep an eye on the company's financial maneuvers.
Diagnos Inc's stock price closed at C$0.23, with a 1D increase of 2.22%.
The stock's 52-week range is between C$0.18 and C$0.42, indicating that it is currently trading at 21% of its range, suggesting limited volatility in recent trading.
Bull case
Analysts have set an average target of C$1.50 for Diagnos Inc, indicating a potential upside of 552.2% from the current price. This optimistic outlook may attract investors seeking growth opportunities in the healthcare sector.
Bear case
Despite the potential for growth, the company's financial health raises concerns. With a profit margin of 0.0% and a return on equity of -990.3%, these factors may deter risk-averse investors.
Price Action
Advertisement
This week, Diagnos Inc's stock experienced a modest increase of 2.22% on Friday, closing at C$0.23. The stock has remained flat over the past week and has seen a significant decline of 36.11% year-to-date.
Recent Company News
While there were no major announcements this week, Diagnos Inc has recently been in the news for amendments to its convertible debentures. The company announced an extension of the maturity date for several convertible debentures, which may help in managing its debt obligations and provide some financial flexibility moving forward.
Technical Picture
Diagnos Inc's technical indicators show a last close at C$0.23, which is slightly above its 50-day moving average of C$0.23 (+1.1%). However, it is significantly below the 200-day moving average of C$0.28 (-19.2%). The stock's 52-week range is C$0.18 to C$0.42, indicating it is currently trading at 21% of this range. The stock has a beta of -0.16, suggesting it is less volatile compared to the market. Volume for the day reached 153,500 shares, which is slightly below the 20-day average volume of 159,952 shares, indicating lower trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
